Review





Similar Products

progenesis qi  (Bruker Corporation)
98
Bruker Corporation progenesis qi
Progenesis Qi, supplied by Bruker Corporation, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/progenesis qi/product/Bruker Corporation
Average 98 stars, based on 1 article reviews
progenesis qi - by Bioz Stars, 2026-05
98/100 stars
  Buy from Supplier
progenesis qi (v2.3)  (Nonlinear Dynamics)
90
Nonlinear Dynamics progenesis qi (v2.3)
Progenesis Qi (V2.3), supplied by Nonlinear Dynamics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/progenesis qi (v2.3)/product/Nonlinear Dynamics
Average 90 stars, based on 1 article reviews
progenesis qi (v2.3) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
progenesis qi v2.3 software  (Nonlinear Dynamics)
90
Nonlinear Dynamics progenesis qi v2.3 software
Progenesis Qi V2.3 Software, supplied by Nonlinear Dynamics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/progenesis qi v2.3 software/product/Nonlinear Dynamics
Average 90 stars, based on 1 article reviews
progenesis qi v2.3 software - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
progenesis qi  (Nonlinear Dynamics)
90
Nonlinear Dynamics progenesis qi
Orthogonal partial least squares discriminant analysis score plots illustrating the separation between biologically compliant placebo controls (red data points) and B vitamin–treated individuals (blue data points) based on serum <t>metabolomic</t> profiling. Results are presented for each individual metabolomic platform (follow‐up timepoint) and for the integrated dataset (baseline and follow‐up timepoints): (A) combination of all four platforms (baseline); (B) NMR (follow‐up); (C) RPLC‐MS (positive ionization mode; follow‐up); (D) RPLC‐MS (negative ionization mode; follow‐up); (E) AEC‐MS (negative ionization mode; follow‐up); (F) combination of all four platforms (follow‐up). “Baseline” refers to samples collected prior to any intervention, and “follow‐up” refers to samples collected after 2 years of B vitamin supplementation or placebo administration. Each model includes accuracy, sensitivity, and specificity (mean ± SD) derived from cross‐validation. Statistical significance ( p > 0.05 ns; p < 0.001***) was assessed relative to a random class ensemble using the Kolmogorov–Smirnov test. AEC‐MS, anion‐exchange chromatography mass spectrometry; NMR, nuclear magnetic resonance; RPLC‐MS, reversed‐phase liquid chromatography mass spectrometry; SD, standard deviation.
Progenesis Qi, supplied by Nonlinear Dynamics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/progenesis qi/product/Nonlinear Dynamics
Average 90 stars, based on 1 article reviews
progenesis qi - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
progenesis qi v3.0 software  (Nonlinear Dynamics)
90
Nonlinear Dynamics progenesis qi v3.0 software
Orthogonal partial least squares discriminant analysis score plots illustrating the separation between biologically compliant placebo controls (red data points) and B vitamin–treated individuals (blue data points) based on serum <t>metabolomic</t> profiling. Results are presented for each individual metabolomic platform (follow‐up timepoint) and for the integrated dataset (baseline and follow‐up timepoints): (A) combination of all four platforms (baseline); (B) NMR (follow‐up); (C) RPLC‐MS (positive ionization mode; follow‐up); (D) RPLC‐MS (negative ionization mode; follow‐up); (E) AEC‐MS (negative ionization mode; follow‐up); (F) combination of all four platforms (follow‐up). “Baseline” refers to samples collected prior to any intervention, and “follow‐up” refers to samples collected after 2 years of B vitamin supplementation or placebo administration. Each model includes accuracy, sensitivity, and specificity (mean ± SD) derived from cross‐validation. Statistical significance ( p > 0.05 ns; p < 0.001***) was assessed relative to a random class ensemble using the Kolmogorov–Smirnov test. AEC‐MS, anion‐exchange chromatography mass spectrometry; NMR, nuclear magnetic resonance; RPLC‐MS, reversed‐phase liquid chromatography mass spectrometry; SD, standard deviation.
Progenesis Qi V3.0 Software, supplied by Nonlinear Dynamics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/progenesis qi v3.0 software/product/Nonlinear Dynamics
Average 90 stars, based on 1 article reviews
progenesis qi v3.0 software - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
progenesis qi software  (Biomark Inc)
90
Biomark Inc progenesis qi software
Orthogonal partial least squares discriminant analysis score plots illustrating the separation between biologically compliant placebo controls (red data points) and B vitamin–treated individuals (blue data points) based on serum <t>metabolomic</t> profiling. Results are presented for each individual metabolomic platform (follow‐up timepoint) and for the integrated dataset (baseline and follow‐up timepoints): (A) combination of all four platforms (baseline); (B) NMR (follow‐up); (C) RPLC‐MS (positive ionization mode; follow‐up); (D) RPLC‐MS (negative ionization mode; follow‐up); (E) AEC‐MS (negative ionization mode; follow‐up); (F) combination of all four platforms (follow‐up). “Baseline” refers to samples collected prior to any intervention, and “follow‐up” refers to samples collected after 2 years of B vitamin supplementation or placebo administration. Each model includes accuracy, sensitivity, and specificity (mean ± SD) derived from cross‐validation. Statistical significance ( p > 0.05 ns; p < 0.001***) was assessed relative to a random class ensemble using the Kolmogorov–Smirnov test. AEC‐MS, anion‐exchange chromatography mass spectrometry; NMR, nuclear magnetic resonance; RPLC‐MS, reversed‐phase liquid chromatography mass spectrometry; SD, standard deviation.
Progenesis Qi Software, supplied by Biomark Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/progenesis qi software/product/Biomark Inc
Average 90 stars, based on 1 article reviews
progenesis qi software - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
progenesis qi for proteomics  (Nonlinear Dynamics)
90
Nonlinear Dynamics progenesis qi for proteomics
Orthogonal partial least squares discriminant analysis score plots illustrating the separation between biologically compliant placebo controls (red data points) and B vitamin–treated individuals (blue data points) based on serum <t>metabolomic</t> profiling. Results are presented for each individual metabolomic platform (follow‐up timepoint) and for the integrated dataset (baseline and follow‐up timepoints): (A) combination of all four platforms (baseline); (B) NMR (follow‐up); (C) RPLC‐MS (positive ionization mode; follow‐up); (D) RPLC‐MS (negative ionization mode; follow‐up); (E) AEC‐MS (negative ionization mode; follow‐up); (F) combination of all four platforms (follow‐up). “Baseline” refers to samples collected prior to any intervention, and “follow‐up” refers to samples collected after 2 years of B vitamin supplementation or placebo administration. Each model includes accuracy, sensitivity, and specificity (mean ± SD) derived from cross‐validation. Statistical significance ( p > 0.05 ns; p < 0.001***) was assessed relative to a random class ensemble using the Kolmogorov–Smirnov test. AEC‐MS, anion‐exchange chromatography mass spectrometry; NMR, nuclear magnetic resonance; RPLC‐MS, reversed‐phase liquid chromatography mass spectrometry; SD, standard deviation.
Progenesis Qi For Proteomics, supplied by Nonlinear Dynamics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/progenesis qi for proteomics/product/Nonlinear Dynamics
Average 90 stars, based on 1 article reviews
progenesis qi for proteomics - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


Orthogonal partial least squares discriminant analysis score plots illustrating the separation between biologically compliant placebo controls (red data points) and B vitamin–treated individuals (blue data points) based on serum metabolomic profiling. Results are presented for each individual metabolomic platform (follow‐up timepoint) and for the integrated dataset (baseline and follow‐up timepoints): (A) combination of all four platforms (baseline); (B) NMR (follow‐up); (C) RPLC‐MS (positive ionization mode; follow‐up); (D) RPLC‐MS (negative ionization mode; follow‐up); (E) AEC‐MS (negative ionization mode; follow‐up); (F) combination of all four platforms (follow‐up). “Baseline” refers to samples collected prior to any intervention, and “follow‐up” refers to samples collected after 2 years of B vitamin supplementation or placebo administration. Each model includes accuracy, sensitivity, and specificity (mean ± SD) derived from cross‐validation. Statistical significance ( p > 0.05 ns; p < 0.001***) was assessed relative to a random class ensemble using the Kolmogorov–Smirnov test. AEC‐MS, anion‐exchange chromatography mass spectrometry; NMR, nuclear magnetic resonance; RPLC‐MS, reversed‐phase liquid chromatography mass spectrometry; SD, standard deviation.

Journal: Alzheimer's & Dementia

Article Title: Role of B vitamins in modulating homocysteine and metabolic pathways linked to brain atrophy: Metabolomics insights from the VITACOG trial

doi: 10.1002/alz.70521

Figure Lengend Snippet: Orthogonal partial least squares discriminant analysis score plots illustrating the separation between biologically compliant placebo controls (red data points) and B vitamin–treated individuals (blue data points) based on serum metabolomic profiling. Results are presented for each individual metabolomic platform (follow‐up timepoint) and for the integrated dataset (baseline and follow‐up timepoints): (A) combination of all four platforms (baseline); (B) NMR (follow‐up); (C) RPLC‐MS (positive ionization mode; follow‐up); (D) RPLC‐MS (negative ionization mode; follow‐up); (E) AEC‐MS (negative ionization mode; follow‐up); (F) combination of all four platforms (follow‐up). “Baseline” refers to samples collected prior to any intervention, and “follow‐up” refers to samples collected after 2 years of B vitamin supplementation or placebo administration. Each model includes accuracy, sensitivity, and specificity (mean ± SD) derived from cross‐validation. Statistical significance ( p > 0.05 ns; p < 0.001***) was assessed relative to a random class ensemble using the Kolmogorov–Smirnov test. AEC‐MS, anion‐exchange chromatography mass spectrometry; NMR, nuclear magnetic resonance; RPLC‐MS, reversed‐phase liquid chromatography mass spectrometry; SD, standard deviation.

Article Snippet: The untargeted metabolomics data (both for RPLC‐MS and AEC‐MS) were processed using Progenesis QI (Nonlinear Dynamics, Waters).

Techniques: Derivative Assay, Biomarker Discovery, Chromatography, Mass Spectrometry, Nuclear Magnetic Resonance, Reversed-phase Chromatography, Standard Deviation